Telix Pharmaceuticals (NASDAQ:TLX) Earns "Outperform" Rating from Wedbush

Key Points

• Wedbush has restated an "outperform" rating for Telix Pharmaceuticals, setting a price target of $22.00, indicating a potential upside of 122.33% from the current stock price.
• The company is anticipated to post modest earnings growth, with projections estimating FY2027 earnings at $0.65 EPS.
• Telix's shares have recently declined by 18.2%, trading around $9.90, well below their 52-week high of $30.36.

Telix Pharmaceuticals (NASDAQ:TLX - Get Free Report)'s stock had its "outperform" rating restated by equities research analysts at Wedbush in a note issued to investors on Thursday,Benzinga reports. They currently have a $22.00 price target on the stock. Wedbush's price target would indicate a potential upside of 122.33% from the company's previous close. Wedbush also issued estimates for Telix Pharmaceuticals' Q3 2025 earnings at $0.03 EPS, Q4 2025 earnings at $0.04 EPS, FY2025 earnings at $0.07 EPS, Q1 2026 earnings at $0.06 EPS, Q2 2026 earnings at $0.08 EPS, Q3 2026 earnings at $0.10 EPS, Q4 2026 earnings at $0.12 EPS, FY2026 earnings at $0.37 EPS, Q1 2027 earnings at $0.14 EPS, Q2 2027 earnings at $0.15 EPS and FY2027 earnings at $0.65 EPS.

Other equities analysts also recently issued research reports about the company. HC Wainwright assumed coverage on Telix Pharmaceuticals in a report on Thursday, July 3rd. They issued a "buy" rating and a $23.00 price objective for the company. William Blair reissued an "outperform" rating on shares of Telix Pharmaceuticals in a research report on Wednesday, July 9th. Four equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $22.33.

Telix Pharmaceuticals Trading Down 18.2%

Shares of Telix Pharmaceuticals stock opened at $9.90 on Thursday. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.66 and a current ratio of 2.78. The business has a 50 day moving average of $14.20 and a 200 day moving average of $16.16. Telix Pharmaceuticals has a 52 week low of $9.95 and a 52 week high of $30.36.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in TLX. Private Advisor Group LLC purchased a new position in Telix Pharmaceuticals in the 1st quarter worth approximately $170,000. IHT Wealth Management LLC purchased a new position in Telix Pharmaceuticals in the 2nd quarter worth approximately $213,000. Blair William & Co. IL purchased a new position in Telix Pharmaceuticals in the 2nd quarter worth approximately $217,000. Vanguard Personalized Indexing Management LLC purchased a new position in Telix Pharmaceuticals in the 2nd quarter worth approximately $297,000. Finally, ABC Arbitrage SA purchased a new position in Telix Pharmaceuticals in the 1st quarter worth approximately $451,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.